Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume
Tóm tắt
Từ khóa
Tài liệu tham khảo
Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706–714
Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156
Worldwide cancer statistics (2015) Cancer research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer#heading-Zero . Accessed 2 Aug 2015
Guckenberger M, Allgäuer M, Appold S et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8:1050–1058
Pass HI, Carbone DP, Johnson DH et al (2012) Principles and practice of lung cancer: the official reference text of the International Association for the Study of Lung Cancer (IASLC). Lippincott Williams & Wilkins, Philadelphia
Semrau S, Bier A, Thierbach U et al (2007) 6‑year experience of concurrent radiochemotherapy with vinorelbine plus a platin compound in multimorbid or aged patients with inoperable non-small cell lung cancer. Strahlenther Onkol 1:30–35
Oberije C, De Ruysscher D, Houben R et al (2015) A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients. Int J Radiat Oncol Biol Phys 92:935–944
Eberhardt WE, Pöttgen C, Gauler TC et al (2015) Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 33(35):4194–4201
Baisi A, Raveglia F, De Simone M et al (2013) Micrometastasis and skip metastasis as predictive factors in no small-cell lung cancer staging. Eur J Cardiothorac Surg 5:1075
Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225–239
Bache M, Kappler M, Said HM et al (2008) Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 15:322–338
Ostheimer C, Bache M, Güttler A et al (2014) A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol 190:276–282
Ostheimer C, Bache M, Güttler A et al (2014) Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. Bmc Cancer 14:858
Duffy MJ, McGowan PM, Gallagher WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214:283–293
McMahon B, Kwaan HC (2008) The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 36:184–194
Dass K, Ahmad A, Azmi AS et al (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 34:122–136
de Bock CE, Wang Y (2004) Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24:13–39
Mondino A, Blasi F (2004) uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25:450–455
Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10:39–49
Brünner N, Foekens J, Harbeck N et al (2010) Characteristics of the levelof-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 10:947–962
Schmitt M, Mengele K, Napieralski R et al (2010) Clinical utility of level-ofevidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI. Expert Rev Mol Diagn 10:1051–1067
Choong PF, Fernö M, Akerman M et al (1996) Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 69:268–272
Taubert H, Würl P, Greither T et al (2010) Codetection of members of the urokinase plasminogen activator system in tumor tissue and in serum correlates with a poor prognosis for softtissue sarcoma patients. Br J Cancer 102:731–737
He C, He P, Liu LP et al (2001) Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells. J Cancer Res Clin Oncol 127:180–186
Hundsdorfer B, Zeilhofer HF, Bock KP (2005) Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity—clinical relevance and prognostic value. J Craniomaxillofac Surg 33:191–196
Sprague LD, Mengele K, Schilling D et al (2006) Effect of reoxygenation on the hypoxia-induced up-regulation of serine protease inhibitor PAI-1 in head and neck cancer cells. Oncology 71:282–291
Bayer C, Schilling D, Hoetzel J et al (2008) PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. Radiother Oncol 86:361–368
Vaschetto R, Navalesi P, Clemente N et al (2015) Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release. Minerva Anestesiol 81:157–165
Das R, Philip S, Mahabeleshwar GH et al (2005) Osteopontin: it’s role in regulation of cell motility and nuclear factor kappa B‑mediated urokinase type plasminogen activator expression. IUBMB Life 57:441–447
Sheng XJ, Zhou DM, Liu Q et al (2014) BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells. Eur J Gynaecol Oncol 35:236–242
Furger KA, Menon RK, Tuck AB et al (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632
Swartz JE, Pothen AJ, Stegeman I et al (2015) Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review. Cancer Med 4:1101–1116
Tuck AB, Hota C, Chambers AF et al (2001) Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70:197–204
Chen RX, Xia YH, Xue TC et al (2011) Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep 38:3671–3677
Das R, Mahabeleshwar GH, Kundu GC et al (2004) Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c‑Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279:11051–11064
Das R, Mahabeleshwar GH, Kundu GC et al (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3‑kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278:28593–28606
Angenete E, Langenskiöld M, Palmgren I (2009) uPA and PAI-1 in rectal cancer—relationship to radiotherapy and clinical outcome. J Surg Res 153:46–53
Salden M, Splinter TA, Peters HA et al (2000) The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 11:327–332
Brünner N, Nielsen HJ, Hamers M et al (1999) The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 107:160–167
Pappot H, Høyer-Hansen G, Rønne E et al (1997) Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 33:867–872
Yang SF, Hsieh YS, Lin CL et al (2005) Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 354:91–99
Kotzsch M, Magdolen V, Greither T et al (2011) Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. BMC Cancer 11:273
Harbeck N, Kates R, Gauger K et al (2004) Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 91:450–456
Castelló R, Landete JM, España F et al (2007) Expression of plasminogen activatorinhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb Res 120:753–762
Xue A, Scarlett CJ, Jackson CJ et al (2008) Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 36:160–167
Biermann JC, Holzscheiter L, Kotzsch M et al (2008) Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med 21:251–259
Schmidt U, Fuessel S, Koch R et al (2006) Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 66:1521–1534
Hsu LH, Hsu PC, Liao TL et al (2016) Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study. BMC Cancer 16:463
Brown LF, Papadopoulos-Sergiou A, Berse B et al (1994) Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610–623
Hu Z, Lin D, Yuan J et al (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646–4652
Zhao B, Sun T, Meng F et al (2011) Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 137:1061–1070
Pavey SJ, Hawson GA, Marsh NA et al (2001) Impact of the fi brinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 12:51–58
Nagamine Y, Medcalf RL, Muñoz-Cánoves P et al (2005) Transcriptional and posttranscriptional regulation of the plasminogen activator system. Thromb Haemost 93:661–675
Volm M, Mattern J, Koomagi R et al (1999) Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol Rep 6:611–615
Hoyer-Hansen G, Lund IK et al (2007) Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 44:65–102
Nijziel MR, Van Oerle R, Hellenbrand D et al (2003) The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J Thromb Haemost 1:982–986
Duffy MJ, Duggan C (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37:541–548
Halamkova J (2011) Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients. Hepatogastroenterology 58:1918–1925
Kwaan HC, Mazar AP, McMahon BJ et al (2013) The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 39:382–391
Almasi CE et al (2011) Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis. Lung Cancer 74(3):510–515
Langenskiöld M, Holmdahl L, Angenete E et al (2009) Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 30:210–220
Käsmann L, Niyazi M, Blanck O et al (2017) Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: a systematic review. Strahlenther Onkol. https://doi.org/10.1007/s00066-017-1221-y
Gunther S, Ostheimer C, Stangl S et al (2015) Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and Adeno non-small cell lung cancer. Front Immunol 6:556